Ebola Vaccine Market By Virus Strain (Chimpanzee Adeno Virus Type 3-Zaire Ebola Virus, Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus, And Adeno Virus Serotype 26- Zaire Ebola Virus), and Region - Global Forecast to 2028
3rd June 2019
find_in_page Our Research Methodology is based on the following main points:
- Data Collections and Interpretation
- Data Validation
- Final Projections and Conclusion
The global Ebola vaccine market is expected to value at over US$ 0.005 Bn in 2019 and is expected to register a CAGR of 32.8%. The global Ebola vaccine market is segmented on the basis of virus strain and region.
Global Ebola Vaccine Market: Introduction
Ebola hemorrhagic fever (EHF) is also referred as Ebola virus disease (EVD) or Ebola, which causes serious illness and sometimes results in fatality if untreated. After the Ebola virus infection or attack, the human body shows symptoms such as high fever, vomiting, sore throat, diarrhea, headache, and muscular pain. Also, in some cases external or internal bleeding also happens. The vaccine that is used to treat Ebola virus disease is referred as Ebola vaccine.
Global Ebola Vaccine Market: Dynamics
Increasing prevalence of Ebola is a major factor expected to drive growth of the global Ebola vaccine market over the forecast period. In addition, increasing government expenditure for the development of healthcare infrastructure in order to facilitate advanced and cost-effective health services is another factor expected to further support growth of the market to a certain extent. For instance, according to a document published by the World Health Organization (WHO) in November 2018, Congo Ministry of Health announced the launch of randomized control trial (RCT) for Ebola therapeutics.
RCT is used to enroll and treat patients at Ebola treatment centers in Butembo and Beni. Moreover, growing demand for new medical equipment and medicines among end users, coupled with growing investments for R&D activities related to the development of effective medicines are major factors driving growth of the global Ebola vaccine market. Furthermore, increasing clinical trials for finding effective and permanent solutions in order to cure or slow down and prevent diseases is a factor propelling growth of the target market.
However, high-cost associated with research and development activities and product recalls are some factors expected to hamper growth of the target market. Product recalls occurs when medical devices are defective or pose risks to the health of individuals. Product recalls by manufacturers are done in order to address problems related to medical devices that violate or do not adhere or comply with government regulations, as well as the high cost of procedures. In addition, lack of proper reimbursement policies in developing countries and limitations to effective first-line of treatment is another factor that could affect growth of the global market.
Whereas, operational costs of clinical trials are comparatively lower in BRIC countries (Brazil, Russia, India, and China), and regulatory and ethics filings process is faster, which can help to reduce overall time and expenses to a significant extent. For instance, In July 2017, according to data published by ClinicalTrials.gov, BRIC countries (Brazil, Russia, India, and China), can execute clinical trials at costs around half of the costs in the US. These countries have marked increased number of trials in recent years. Moreover, 36% of clinical trials were conducted in the US, and 47% of trials were conducted in non-US countries the same year.
Also, leading players are engaged with new product development, which is expected to support growth of the target market in the next ten years. For instance, GlaxoSmithKline plc – a leading player in the healthcare market has developed CAd3-ZEBOV vaccine. This vaccine is derived from chimpanzee adenovirus and phase 3 clinical trials were conducted in February 2016. In addition, as per Lancet, a medical journal, NewLink Genetics Corporation and Merck & Co., Inc., has developed V920 vaccine (rVSV-ZEBOV) in December 2016, which they found effective against Ebola virus disease in phase three clinical trial.
Global Ebola Vaccine Market Analysis, by Virus Strain
Among the virus strain segments, the recombinant vesicular stomatitis virus-Zaire Ebola virus segment is expected to account for major revenue share and is expected to maintain its dominance over the forecast period. The recombinant vesicular stomatitis virus-Zaire Ebola virus segment is expected to register CAGR of over 34.5%. The chimpanzee adenovirus type 3-Zaire Ebola virus segment accounts for second highest share in terms of revenue in the near future.
Global Ebola Vaccine Market Analysis, by Region
Currently, the market in North America is dominating the global market in terms of revenue and is expected to maintain its dominance over the forecast period. Presence of prominent pharmaceutical manufacturing companies, coupled with increasing investment for drug development activity are major factors driving growth of the Ebola vaccine market in North America.
The Ebola vaccine market in Europe accounts for second-highest share in terms of revenue and is expected to register lucrative growth in the near future. Increasing government support for research and development for treatment and clinical trials especially in countries such as Germany and the UK is a major factor expected to fuel growth of the target market in this region. In addition, presence of major players operating in the target market is another factor expected to support growth of the Ebola vaccine market in Europe over the forecast period.
Market in the Asia Pacific is expected to register the fastest growth in terms of revenue in the near future. Increasing demand for medical drugs and devices is a factor supporting growth of the target market in this region. In addition, increasing investment by government and private sectors in order to provide medicines and medical treatment in affordable cost and growing geriatric population are factors anticipated to support growth of the Ebola vaccine market in Asia Pacific market over the forecast period.
The market in Middle East & Africa is expected to witness lucrative growth in terms of revenue over the forecast period, followed by the market in Latin America.
Global Ebola Vaccine Market Segmentation:
Global Ebola Vaccine Market Segmentation, By Virus Strain:
- Chimpanzee Adeno virus type 3-Zaire Ebola virus
- Recombinant vesicular stomatitis virus-Zaire Ebola virus
- Adeno virus serotype 26- Zaire Ebola Virus
Global Ebola Vaccine Market Segmentation, by Region:
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
- Sarepta Therapeutics Inc.
- Mapp Biopharmaceutical Inc.
- Regeneron Pharmaceuticals, Inc.
- Merck & Company, Inc.
- GlaxoSmithKline plc.
- Novavax Inc.
- GeoVax Labs Inc.
- Chapter 1
- 1.1 Preface
- 1.2 Assumptions
- 1.3 Abbreviations
- 2.0 Chapter 2
- 2.1 Report Description
- 2.1.1 Market Definition and Scope
- 2.2 Executive Summary
- 2.2.1 Market Snapshot, By Virus Strain
- 2.2.2 Market Snapshot, By Region
- 2.2.3 Prudour Opportunity Map Analysis
- 2.1 Report Description
- 3.0 Chapter 3
- Chapter 1
Don't just take our word. We are trusted by these great companies!